Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

被引：48

作者：

Delaugerre, C

Marcelin, AG

Thibault, V

Peytavin, G

Bombled, T

Bochet, MV

Katlama, C

Benhamou, Y

Calvez, V

机构：

[1] Hop La Pitie Salpetriere, Dept Virol, Paris, France

[2] Hop La Pitie Salpetriere, Dept Hepatol, Paris, France

[3] Hop La Pitie Salpetriere, Dept Infect Dis, Paris, France

[4] Hop Bichat Claude Bernard, Dept Clin Pharmacol, F-75877 Paris 18, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 05期

关键词：

D O I：

10.1128/AAC.46.5.1586-1588.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.

引用

页码：1586 / 1588

页数：3

共 16 条

[1] Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients [J].

BarditchCrovo, P ;

Toole, J ;

Hendrix, CW ;

Cundy, KC ;

Ebeling, D ;

Jaffe, HS ;

Lietman, PS .

JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (02) :406-413

[2] Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study [J].

Benhamou, Y ;

Bochet, M ;

Thibault, V ;

Calvez, V ;

Fievet, MH ;

Vig, P ;

Gibbs, CS ;

Brosgart, C ;

Fry, J ;

Namini, H ;

Katiama, C ;

Poynard, T .

LANCET, 2001, 358 (9283) :718-723

[3] Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay [J].

Boucher, CAB ;

Keulen, W ;

vanBommel, T ;

Nijhuis, M ;

DeJong, D ;

DeJong, MD ;

Schipper, P ;

Back, NKT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2404-2409

[4] Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro [J].

Cherrington, JM ;

Mulato, AS ;

Fuller, MD ;

Chen, MS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2212-2216

[5] The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized, double-blind, placebo-controlled trial [J].

Deeks, SG ;

Collier, A ;

Lalezari, J ;

Pavia, A ;

Rodrigue, D ;

Drew, WL ;

Toole, J ;

Jaffe, HS ;

Mulato, AS ;

Lamy, PD ;

Li, WX ;

Cherrington, JM ;

Hellmann, N ;

Kahn, J .

JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1517-1523

[6]

Gilson RJC, 1998, HEPATOLOGY, V28, p491A

[7] K65R MUTATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE ENCODES CROSS-RESISTANCE TO 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE [J].

GU, ZX ;

SALOMON, H ;

CHERRINGTON, JM ;

MULATO, AS ;

CHEN, MS ;

YARCHOAN, R ;

FOLI, A ;

SOGOCIO, KM ;

WAINBERG, MA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1888-1891

[8]

Heathcote EJ, 1998, HEPATOLOGY, V28, p317A

[9] Antiretroviral drug resistance testing in adult HIV-1 infection -: Recommendations of an International AIDS Society-USA panel [J].

Hirsch, MS ;

Brun-Vézinet, F ;

D'Aquila, RT ;

Hammer, SM ;

Johnson, VA ;

Kuritzkes, DR ;

Loveday, C ;

Mellors, JW ;

Clotet, B ;

Conway, B ;

Demeter, LM ;

Vella, S ;

Jacobsen, DM ;

Richman, DD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (18) :2417-2426

[10] Efficacy and safety of adefovir dipivoxil with antiretroviral therapy - A randomized controlled trial [J].

Kahn, J ;

Lagakos, S ;

Wulfsohn, M ;

Cherng, D ;

Miller, M ;

Cherrington, J ;

Hardy, D ;

Beall, G ;

Cooper, R ;

Murphy, R ;

Basgoz, N ;

Ng, E ;

Deeks, S ;

Winslow, D ;

Toole, JJ ;

Coakley, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (24) :2305-2312

← 1 2 →